Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

Biotechnology

Outlook Therapeutics

C. Russell Trenary III

Tony Moses

Surendra Sharma

Christoph Puetz

Lauren Nelson

Kathleen Billman

Jennifer Kissner

Entisar Dahan, MPM, PHR

Anu Wallecha

Terry Dagnon

Lawrence A. Kenyon

Jeff Evanson

The Operations Team at Outlook Therapeutics is responsible for ensuring the seamless production, compliance, and delivery of ONS-5010 / LYTENAVA™ (bevacizumab-vikg). This includes overseeing manufacturing processes, supply chain management, quality assurance, and commercial operations to support the successful development and market introduction of the ophthalmic formulation for retinal diseases.

Operations Team

Directors

Leadership Team

Operations Team

About

Team members

Other teams at Outlook Therapeutics

Directors

Leadership Team